Aspro Abdullah Ely

Abdullah Ely is a researcher in molecular biotechnology and gene therapy, with a strong focus on hepatitis B virus research and RNA-based therapeutics. His work is closely associated with advancing innovative treatment strategies for chronic HBV infection, particularly within the African context. Ely’s scholarship integrates virology, synthetic RNA technologies, and translational medicine to address persistent viral diseases and vaccine inequity.

His publications highlight expertise in artificial primary microRNAs, adeno-associated viral vectors, and in vitro transcribed mRNA platforms. A central theme is the development of gene silencing and gene therapy approaches targeting HBV, including durable suppression of viral gene expression and improved safety profiles. He has also contributed to refining animal models that recapitulate HBV subgenotypes prevalent in sub-Saharan Africa.

Ely’s research further extends to self-amplifying RNA vaccines and lipid nanoparticle delivery systems, bridging gene therapy and next-generation vaccine technologies. His work emphasizes scalable manufacturing, hepatotropic delivery, and context-specific solutions to strengthen therapeutic innovation and pandemic preparedness in low- and middle-income regions.